Dirk Strumberg

9.6k citations

141 papers · 7.4k indexed · 1 hit paper · h-index 42

Impact in

Oncology top 0.5%
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
Toxicology top 0.5%

Papers in

Oncology 78
- Colorectal Cancer Treatments and Studies 40
- Cancer Treatment and Pharmacology 31
- Pancreatic and Hepatic Oncology Research 12
Hepatology 10
- Hepatocellular Carcinoma Treatment and Prognosis 10

Co-authors: M. E. Scheulen Yves Pommier Ralf A. Hilger S. Seeber Beate Schultheis Heike Richly Brian Schwartz Yi Fan
Journals: Journal of Clinical Oncology (26 papers)Annals of Oncology (11 papers)European Journal of Cancer (7 papers)British Journal of Cancer (7 papers)Anti-Cancer Drugs (4 papers)
Partner nations: Germany United States Switzerland

In The Last Decade

Dirk Strumberg

138 papers receiving 7.3k citations

Hit Papers

align trajectories log scale

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors 2004 · 694 citations

Peers

Countries citing papers authored by Dirk Strumberg

Since Specialization

Citations

This map shows the geographic impact of Dirk Strumberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Strumberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Strumberg more than expected).

Fields of papers citing papers by Dirk Strumberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Strumberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Strumberg. The network helps show where Dirk Strumberg may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Dirk Strumberg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Dirk Strumberg Line = papers co-authored together Dirk Strumberg links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	1424MO Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma– Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM Annals of Oncology ·S-E. Al-Batran, Ralf‐Dieter Hofheinz, Harald Schmalenberg, Dirk Strumberg, Eray Goekkurt, Stefan Angermeier, Thomas Zander, Jochem Potenberg, H-G. Kopp, Daniel Pink, Gabriele Margareta Siegler, Michael Schenk, F. De Vita, Evaristo Maiello, Timo Gaiser, Disorn Sookthai, D. Masci, Claudia Pauligk, Gaute Fredriksen, Nils Homann	2020	5
2	Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study The Breast ·顾清红, 克憲向井, B. Gerber, Marcus Schmidt, Volker Moebus, Bre- Mer Krebsgesellschaft, Eva‐Maria Grischke, Peter A. Fasching, Dirk Strumberg, Erich‐Franz Solomayer, Peter Klare, 俊佑森, Stefan Hartmann, Andreas Schneeweiß, Frederik Marmé	2019	12
3	A Distinct Oncogenerative Multinucleated Cancer Cell Serves as a Source of Stemness and Tumor Heterogeneity Cancer Research ·David Díaz-Carballo, Jamie Wood, Shiqiong Huang, 塚本孝臣, Li Li, James Wells, Holger Jastrow, Gunther Wennemuth, Clemens Tempfer, Inge Schmitz, Andrea Tannapfel, Dirk Strumberg	2018	62
4	Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study Annals of Oncology ·Beate Schultheis, Dirk Reuter, M. Ebert, Jens T. Siveke, Andrea Kerkhoff, Wolfgang E. Berdel, Ralf‐Dieter Hofheinz, Dirk Behringer, Wolfgang E. Schmidt, Erdem Göker, Sara De Dosso, Michael Kneba, Şuayib Yalçın, Friedrich Overkamp, Frank Schlegel, Yihao Guo, Robert Rohrberg, Hongfeng Wu, Michael Bulitta, Dirk Strumberg	2017	97
5	Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies British Journal of Cancer ·Rastislav Bahleda, Juneko E. Grilley‐Olson, Ramaswamy Govindan, Fabrice Barlési, Laurent Greillier, M. Pérol, Isabelle Ray‐Coquard, Dirk Strumberg, Beate Schultheis, Grace K. Dy, Gérard Zalcman, Glen J. Weiss, Annette O. Walter, Martin Kornacker, Prabhu Rajagopalan, David Henderson, Hendrik Nogai, Matthias Ocker, Jean‐Charles Soria	2017	22
6	Antimetastatic Activity of Atu027, a Liposomal Sirna Formulation, Targeting Protein Kinase N3: Final Results of a Phase I Study Annals of Oncology ·Dirk Strumberg, Beate Schultheis, Ansgar Santel, Frank Gebhardt, W. Meyer‐Sabellek, Oliver Keil, Klaus Giese, Jan O. Kaufmann	2013	3
7	A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network British Journal of Cancer ·K. Mross, Christian Dittrich, Walter E. Aulitzky, Dirk Strumberg, J. Schütte, Roland M. Schmid, S. Hollerbach, Michael Merger, Gerd Munzert, Frank Fleischer, M. E. Scheulen	2012	70
8	Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group) Investigational New Drugs ·Beate Schultheis, Dirk Strumberg, Lothar Bergmann, Ullrich Graeven, Axel-Rainer Hanauske, Rainer W. Lipp, Jochen Schuette, Kaku Saito, P. Scigalla, M. E. Scheulen	2011	12
9	Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors Cancer Chemotherapy and Pharmacology ·Beate Schultheis, Angie Yeliany Ruiz León, Md. Abu Bokkor Shiddik, E. Brendel, Chenjing Xia, Martin Kornacker, Dirk Strumberg	2011	10
10	Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors International Journal of Clinical Pharmacology and Therapeutics ·Dirk Strumberg, Beate Schultheis, Tetsuya Komuku, Christiane Vank, Ansgar Santel, Oliver Keil, Klaus Giese, Jörg Kaufmann, Joachim Drevs	2011	112
11	Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer International Journal of Clinical Pharmacology and Therapeutics ·Dirk Strumberg, Beate Schultheis, M. E. Scheulen, Ralf A. Hilger, Juergen Krauss, Norbert Marschner, Florian Lordick, F. Bach, Dirk Reuter, Lutz Edler, Sile Yu	2010	12
12	Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? European Journal of Cancer ·Dirk Strumberg, Ahmad Awada, Holger W. Hirte, Jeffrey W. Clark, S. Seeber, 徹也重里, 张矣韵, D. Voliotis, O. Christensen, Andreas Brueckner, Brian Schwartz	2006	115
13	Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma Melanoma Research ·Alexander Schmittel, M. E. Scheulen, Nikolaos E. Bechrakis, Dirk Strumberg, Joachim Baumgart, Norbert Bornfeld, Michael Foerster, E. Thiel, Ulrich Keilholz	2005	40
14	Ernährung, Lifestyle und Krebs: Wege zur Primärprävention DMW - Deutsche Medizinische Wochenschrift ·Dirk Strumberg, Heiner Boeing, M. E. Scheulen, H Förster, S. Seeber	2004	1
15	Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation International Journal of Clinical Pharmacology and Therapeutics ·Ralf A. Hilger, Joachim Baumgart, M. E. Scheulen, Rudolf Trenschel, Dirk Strumberg, S. Seeber, Dietrich W. Beelen	2004	5
16	Novel antitumoral compound isolated from Clusia rosea International Journal of Clinical Pharmacology and Therapeutics ·David Díaz-Carballo, S. Seeber, Dirk Strumberg, Ralf A. Hilger	2003	30
17	Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer Annals of Oncology ·Dirk Strumberg, Simone van der Sar–van der Brugge, Lin Li-ping, Susanne Koeppen, J Ranft, Gerd Scheiber, C Reiners, Winifred Spitzer, S. Seeber, M. E. Scheulen	2002	166
18	Conversion of Topoisomerase I Cleavage Complexes on the Leading Strand of Ribosomal DNA into 5′-Phosphorylated DNA Double-Strand Breaks by Replication Runoff Molecular and Cellular Biology ·Dirk Strumberg, André A. Pilon, Melanie Smith, Robert J. Hickey, Linda H. Malkas, Yves Pommier	2000	292
19	A Phase I Dose Escalation Trial of Intravenous Treosulfan in Refractory Cancer Oncology Research and Treatment ·A. Harstrick, Hans‐Joachim Wilke, Wilfried Eberhardt, U. Klaassen, Dirk Strumberg, Michael Korn, M. E. Scheulen, Joachim Baumgart, S. Seeber	1996	20
20	Molecular detection of genetic defects in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: A study of 27 families European Journal of Pediatrics ·Dirk Strumberg, B. P. Hauffa, Bernhard Horsthemke, H. Grosse‐Wilde	1992	6

About Dirk Strumberg

Dirk Strumberg is a scholar working on Oncology, Hepatology, Pulmonary and Respiratory Medicine, Toxicology and Cancer Research, having authored 141 papers that have together received 7.4k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (40 papers), Cancer Treatment and Pharmacology (31 papers), Gastric Cancer Management and Outcomes (18 papers), Melanoma and MAPK Pathways (15 papers), Cancer therapeutics and mechanisms (13 papers), Pancreatic and Hepatic Oncology Research (12 papers), Lung Cancer Treatments and Mutations (12 papers) and Hepatocellular Carcinoma Treatment and Prognosis (10 papers). The work is most often cited by research in Oncology (3.1k citations), Toxicology (311 citations), Hepatology (698 citations), Cancer Research (1.2k citations) and Molecular Biology (3.5k citations). Dirk Strumberg has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include M. E. Scheulen, Yves Pommier, Ralf A. Hilger, S. Seeber, Beate Schultheis, Heike Richly, Brian Schwartz, Yi Fan, Philippe Pourquier and Ahmad Awada. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, British Journal of Cancer and Anti-Cancer Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact